245 related articles for article (PubMed ID: 32372114)
21. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
22. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.
Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M
Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192
[TBL] [Abstract][Full Text] [Related]
23. Pegylated liposomal doxorubicin (Caelyx®) and oral vinorelbine in first-line metastatic breast cancer patients previously treated with anthracyclines.
Livi L; Meattini I; Scotti V; De Luca Cardillo C; Galardi A; Iermano C; Sanchez L; Nori J; Mangoni M; Franzese C; Orzalesi L; Bertocci S; Agresti B; Masoni T; Bianchi S; Cataliotti L; Biti G
J Chemother; 2011 Jun; 23(3):158-62. PubMed ID: 21742585
[TBL] [Abstract][Full Text] [Related]
24. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer.
Huober J; Fett W; Nusch A; Neise M; Schmidt M; Wischnik A; Gerhardt S; Goehler T; Lück HJ; Rost A
BMC Cancer; 2010 Jan; 10():2. PubMed ID: 20047698
[TBL] [Abstract][Full Text] [Related]
25. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
Schneeweiss A; Michel LL; Möbus V; Tesch H; Klare P; Hahnen E; Denkert C; Kast K; Pohl-Rescigno E; Hanusch C; Link T; Untch M; Jackisch C; Blohmer JU; Fasching PA; Solbach C; Schmutzler RK; Huober J; Rhiem K; Nekljudova V; Lübbe K; Loibl S;
Eur J Cancer; 2022 Jan; 160():100-111. PubMed ID: 34801353
[TBL] [Abstract][Full Text] [Related]
26. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.
Zhao M; Ding XF; Shen JY; Zhang XP; Ding XW; Xu B
J Zhejiang Univ Sci B; 2017 Jan.; 18(1):15-26. PubMed ID: 28070993
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
[TBL] [Abstract][Full Text] [Related]
28. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
Alba E; Ruiz-Borrego M; Margelí M; Rodríguez-Lescure A; Sánchez-Rovira P; Ruiz A; Mel-Lorenzo JR; Ramos-Vázquez M; Ribelles N; Calvo E; Casado A; Márquez A; Vicente D; García-Sáenz JA; Martín M
Breast Cancer Res Treat; 2010 Jul; 122(1):169-76. PubMed ID: 20361253
[TBL] [Abstract][Full Text] [Related]
29. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy with a Pegylated Liposomal Doxorubicin-Containing Regimen in Newly Diagnosed Hodgkin Lymphoma Patients.
Liu W; Yang M; Ping L; Xie Y; Wang X; Zhu J; Song Y
Cardiovasc Toxicol; 2021 Jan; 21(1):12-16. PubMed ID: 32683546
[TBL] [Abstract][Full Text] [Related]
31. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
O'Brien ME; Wigler N; Inbar M; Rosso R; Grischke E; Santoro A; Catane R; Kieback DG; Tomczak P; Ackland SP; Orlandi F; Mellars L; Alland L; Tendler C;
Ann Oncol; 2004 Mar; 15(3):440-9. PubMed ID: 14998846
[TBL] [Abstract][Full Text] [Related]
32. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Batist G; Harris L; Azarnia N; Lee LW; Daza-Ramirez P
Anticancer Drugs; 2006 Jun; 17(5):587-95. PubMed ID: 16702817
[TBL] [Abstract][Full Text] [Related]
33. Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line therapy in metastatic breast cancer: a retrospective analysis.
Livi L; Meattini I; Cardillo Cde L; Mangoni M; Greto D; Petrucci A; Rampini A; Bruni A; Galardi A; Cataliotti L; Biti G
Tumori; 2009; 95(4):422-6. PubMed ID: 19856650
[TBL] [Abstract][Full Text] [Related]
34. Pegylated liposomal doxorubicin (PLD) in daily practice-A single center experience of treatment with PLD in patients with comorbidities and older patients with metastatic breast cancer.
Wallrabenstein T; Daetwyler E; Oseledchyk A; Rochlitz C; Vetter M
Cancer Med; 2023 Jun; 12(12):13388-13396. PubMed ID: 37148541
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer.
Chang AE; Wu QV; Jenkins IC; Specht JM; Gadi VK; Gralow JR; Salazar LG; Kurland BF; Linden HM
Clin Breast Cancer; 2018 Feb; 18(1):e143-e149. PubMed ID: 29174203
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study.
Blake EA; Bradley CA; Mostofizadeh S; Muggia FM; Garcia AA; Roman LD; Matsuo K
Arch Gynecol Obstet; 2019 Jun; 299(6):1641-1649. PubMed ID: 30824986
[TBL] [Abstract][Full Text] [Related]
37. Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin.
Liu W; Chen W; Zhang X; Zhao P; Fan Z; Bi L; Wu D; Li S; Yang M; Fu T; Song D; Han B; Zhao G; Du Y; Shi A
Sci Rep; 2021 Jan; 11(1):199. PubMed ID: 33420241
[TBL] [Abstract][Full Text] [Related]
38. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
39. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
[TBL] [Abstract][Full Text] [Related]
40. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.
Minisini AM; Andreetta C; Fasola G; Puglisi F
Expert Rev Anticancer Ther; 2008 Mar; 8(3):331-42. PubMed ID: 18366282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]